Patents by Inventor Yi-Tsui Chiu

Yi-Tsui Chiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY WITH DEUTERATED IMIDAZOQUINOLINES
    Publication number: 20240382469
    Abstract: The present specification provides therapeutic combinations and methods for treating cancers using combination therapy.
    Type: Application
    Filed: September 16, 2022
    Publication date: November 21, 2024
    Inventors: Pei-Jou LEE, Yi-Tsui CHIU, Fu-Tan HSIEH
  • Hepatitis B therapeutic vaccines
    Patent number: 10058606
    Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: August 28, 2018
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
  • HEPATITIS B THERAPEUTIC VACCINES
    Publication number: 20180078636
    Abstract: A fusion protein for use as a hepatitis B therapeutic vaccine is disclosed. The fusion protein comprises: (a) an antigen-presenting cell (APC)-binding domain or a CD91 receptor-binding domain; (b) a protein transduction domain; and (c) an antigen comprising a hepatitis B virus X protein deletion mutant that lacks amino acids (aa) at least from as 21 to as 50. The protein transduction domain is a fusion polypeptide comprising a T cell sensitizing signal-transducing peptide, a linker, and a translocation peptide. The APC-binding domain or the CD91 receptor-binding domain is located at the N-terminus of the fusion protein, and the antigen is located at the C-terminus of the protein transduction domain.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 22, 2018
    Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Chia Lin, Kung-Lung Lee, Chia-Hao Kang, Fu-Hsien Chiang, Cheng-Yung Chang, Wei-Lun Chang, Hsiang-Kai Lin, Chia-Kuan Peng, Wei-Hsiang Lin, Yi-Tsui Chiu
  • Vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific T-cell responses
    Patent number: 9775898
    Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: October 3, 2017
    Assignee: TheVax Genetics Vaccine Co., Ltd.
    Inventors: Chia-Mao Wu, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen
  • VACCINE COMPOSITION COMPRISING AN IMMUNOGENIC PROTEIN AND COMBINATION ADJUVANTS FOR USE IN ELICITING ANTIGEN-SPECIFIC T-CELL RESPONSES
    Publication number: 20160250324
    Abstract: Vaccine compositions for use in inducing enhanced antigen-specific T cell-mediated immune responses in a subject in need thereof are disclosed. The composition comprises (a) a therapeutically effective amount of an immunogenic protein comprising at least an antigen of a pathogen; (b) a saponin-base adjuvant selected from the group consisting of GPI-0100, Quil A, QS-21; and (c) a Toll-like receptor (TLR) agonist adjuvant selected from the group consisting of monophosphoryl lipid A (MPL), and CpG1826.
    Type: Application
    Filed: February 24, 2016
    Publication date: September 1, 2016
    Inventors: Chia-Mao WU, Jiun-Ming Wu, Yi-Tsui Chiu, Yin-Ching Lin, Hsien-Kai Chuang, Fu-Tan Hsieh, Kuan-Ming Chen